AEterna Zentaris Inc. (AEZS)

[alexander77]

Maxim Maintains Buy on AEterna Zentaris Inc. (AEZS) as Saizen Promotion Begins
July 27, 2015 5:12 PM EDT by Kate George, Editor in Exclusively Published • Healthcare • Insights
Maxim Group analyst Jason Kolbert weighed in today with his views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), following the news that the company has commenced the promotion of EMD Serono’s Saizen, an injectable recombinant growth hormone for the treatment of growth hormone deficiency. The analyst rates AEZS a Buy with a $2.00 price target, which implies an upside of 962% from current levels.

In his research note, Kolbert noted, “Commencing the Saizen promotion is a positive for the company and should provide revenues that offset operating expenses from larger programs like Zoptarelin-Dox (AEZS-108), currently in a fully enrolled phase III study endometrial cancer. Importantly, promotion of Saizen in the GHD market is building marketing infrastructure for a potential launch of Macrilin (stimulated GH secretion) which is re-entering the clinic in a pivotal phase III study.”

“With each new patient representing $30K, we estimate that Aeterna can generate $16M in high-margin revenue. In a billion dollar market, this may even be an underestimate.”, the analyst concluded.

http://www.smarteranalyst.com/2015/07/27/maxim-maintains-buy-on-aeterna-zentaris-inc-usa-as-saizen-promotion-begins/

So $16M/annually revenues for Saizen is GREAT!